Russell H. Plumb
Plus aucun poste en cours
Historique de carrière de Russell H. Plumb
Anciens postes connus de Russell H. Plumb
Sociétés | Poste | Début | Fin |
---|---|---|---|
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | Directeur/Membre du Conseil | 07/07/2011 | 13/02/2012 |
Directeur Financier/CFO | 01/08/2000 | 13/02/2012 | |
President | 01/08/2000 | 13/02/2012 | |
Secrétaire Général | 01/08/2000 | 13/02/2012 | |
Treasurer | 01/08/2000 | 13/02/2012 | |
Emory Vision | Directeur Financier/CFO | 01/12/1999 | 01/07/2000 |
Serologicals Corp.
Serologicals Corp. Miscellaneous Commercial ServicesCommercial Services Serologicals Corp. researches, develops and markets biological products for the life sciences market. The firm focuses in areas such as are cell culture supplements, molecular reagents and diagnostic antibodies. Its applications include cardiology, hematology, infectious diseases, immunology, molecular biology and oncology. It has operations in Australia, Canada, Scotland, and United Kingdom. The company was founded in 1971 by Samuel A. Penninger and is located in Norcross, GA. | Directeur Financier/CFO | 01/01/1994 | 01/11/1999 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Directeur/Membre du Conseil | 14/11/2012 | 01/10/2014 |
Directeur Général | 14/11/2012 | 01/10/2014 | |
Président | 01/10/2014 | - | |
Directeur Financier/CFO | 12/11/2012 | 02/11/2015 | |
President | 14/11/2012 | 01/10/2014 | |
Secrétaire Général | 12/11/2012 | - | |
Treasurer | 12/11/2012 | - | |
AerovectRx Corp.
AerovectRx Corp. Pharmaceuticals: MajorHealth Technology AerovectRx Corp. provides dosage controlled solutions to the inhaled drug delivery market. It offers AeroCell disposable drug cartridge for inhaled delivery of drugs, vaccines, and therapeutics. AerovectRx technology includes treatments for asthma, cystic fibrosis, pulmonary hypertension, chronic obstructive pulmonary disease (COPD), diabetes, pain management and for delivery of vaccines and anti-viral drugs. The company was founded in 2005 and is headquartered in Atlanta, GA. | Directeur/Membre du Conseil | 25/03/2010 | - |
Formation de Russell H. Plumb
University of Toronto | Masters Business Admin |
Statistiques
Internationale
Etats-Unis | 6 |
Canada | 2 |
Opérationnelle
Director of Finance/CFO | 4 |
Director/Board Member | 3 |
President | 2 |
Sectorielle
Health Technology | 4 |
Consumer Services | 2 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 5 |
---|---|
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | Health Technology |
Emory Vision | |
Serologicals Corp.
Serologicals Corp. Miscellaneous Commercial ServicesCommercial Services Serologicals Corp. researches, develops and markets biological products for the life sciences market. The firm focuses in areas such as are cell culture supplements, molecular reagents and diagnostic antibodies. Its applications include cardiology, hematology, infectious diseases, immunology, molecular biology and oncology. It has operations in Australia, Canada, Scotland, and United Kingdom. The company was founded in 1971 by Samuel A. Penninger and is located in Norcross, GA. | Commercial Services |
AerovectRx Corp.
AerovectRx Corp. Pharmaceuticals: MajorHealth Technology AerovectRx Corp. provides dosage controlled solutions to the inhaled drug delivery market. It offers AeroCell disposable drug cartridge for inhaled delivery of drugs, vaccines, and therapeutics. AerovectRx technology includes treatments for asthma, cystic fibrosis, pulmonary hypertension, chronic obstructive pulmonary disease (COPD), diabetes, pain management and for delivery of vaccines and anti-viral drugs. The company was founded in 2005 and is headquartered in Atlanta, GA. | Health Technology |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Health Technology |
- Bourse
- Insiders
- Russell H. Plumb
- Expérience